Literature DB >> 27890655

Silver nanoparticle treatment ameliorates biliary atresia syndrome in rhesus rotavirus inoculated mice.

Ruizhong Zhang1, Zefeng Lin1, Vincent C H Lui2, Kenneth K Y Wong2, Paul K H Tam2, Puiyan Lee3, Chun Nam Lok3, Jonathan R Lamb4, Yan Chen5, Huimin Xia6.   

Abstract

Biliary atresia (BA) is a neonatal biliary system disease closely associated with viral infection and bile duct inflammation. Silver nanoparticles (AgNps) have previously revealed antiviral and anti-inflammatory properties. In this study, we have investigated the effects of AgNps in the treatment of the Rhesus rotavirus inoculation induced BA in mice. The morphology, liver histopathology, clinical biochemistry examination, and inflammatory cells were analyzed in BA mice. Results indicated that AgNps could significantly increase the survival rate of BA mice, and reduce jaundice and weight lost and the liver enzymes and bilirubin metabolism clinical parameters were close to the normal levels. Diminished numbers of NK cells were observed by flow cytometry analysis and immunohistochemical staining. Furthermore, the viral load was reduced and transcripts for TGF-β mRNA were augmented after AgNps treatment. Collectively, our results suggest that AgNps treatment has beneficial effects on the BA mouse model partially through upregulation of TGF-β.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biliary atresia; NK cells, TGF-β, hepatic inflammation; Silver nanoparticles

Mesh:

Substances:

Year:  2016        PMID: 27890655     DOI: 10.1016/j.nano.2016.11.013

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  8 in total

Review 1.  Recent advances on therapeutic potentials of gold and silver nanobiomaterials for human viral diseases.

Authors:  Yusuf Oloruntoyin Ayipo; Ajibola Abdulahi Bakare; Umar Muhammad Badeggi; Akeem Adebayo Jimoh; Amudat Lawal; Mohd Nizam Mordi
Journal:  Curr Res Chem Biol       Date:  2022-02-01

2.  A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice.

Authors:  Ming Fu; Zefeng Lin; Huiting Lin; Yanlu Tong; Hezhen Wang; Hongjiao Chen; Yan Chen; Ruizhong Zhang
Journal:  J Vis Exp       Date:  2018-10-13       Impact factor: 1.355

3.  Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus.

Authors:  Yinghua Li; Zhengfang Lin; Min Guo; Yu Xia; Mingqi Zhao; Changbing Wang; Tiantian Xu; Tianfeng Chen; Bing Zhu
Journal:  Int J Nanomedicine       Date:  2017-08-09

Review 4.  Silver-Based Nanomaterials as Therapeutic Agents Against Coronaviruses: A Review.

Authors:  Chanchal Das; Subha Sankar Paul; Arighna Saha; Tejinder Singh; Abhijit Saha; Jungkyun Im; Goutam Biswas
Journal:  Int J Nanomedicine       Date:  2020-11-23

5.  The Inhibition of H1N1 Influenza Virus-Induced Apoptosis by Surface Decoration of Selenium Nanoparticles with β-Thujaplicin through Reactive Oxygen Species-Mediated AKT and p53 Signaling Pathways.

Authors:  Changbing Wang; Haiyang Chen; Danyang Chen; Mingqi Zhao; Zhengfang Lin; Min Guo; Tiantian Xu; Yi Chen; Liang Hua; Tao Lin; Ying Tang; Bing Zhu; Yinghua Li
Journal:  ACS Omega       Date:  2020-11-16

6.  Down-regulation of STAT3 enhanced chemokine expression and neutrophil recruitment in biliary atresia.

Authors:  Ming Fu; Ledong Tan; Zefeng Lin; Vincent C H Lui; Paul K H Tam; Jonathan R Lamb; Yan Zhang; Huimin Xia; Ruizhong Zhang; Yan Chen
Journal:  Clin Sci (Lond)       Date:  2021-04-16       Impact factor: 6.124

Review 7.  The Emerging Roles of Silver Nanoparticles to Target Viral Life Cycle and Detect Viral Pathogens.

Authors:  Ujjyani Ghosh; Khondakar Sayef Ahammed; Snehasis Mishra; Asim Bhaumik
Journal:  Chem Asian J       Date:  2022-01-24

8.  Tri-block polymer with interfacial layer formation ability and its use in maintaining supersaturated drug solution after dissolution of solid dispersions.

Authors:  Ji-Jun Fu; Cheng-Cheng Liu
Journal:  Int J Nanomedicine       Date:  2018-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.